Latest Global Markets News

Citigroup Global Markets Australia has declared a fully franked AUD 0.30 dividend for its ORG CitiFirst Self-Funding Instalment MINIs, reducing outstanding loan amounts and aligning dividend dates with ORG ordinary shares.

Advanced Braking Technology (ABT) reported robust FY25 financial results marked by revenue growth and improved profitability, while advancing its strategic roadmap focused on mining safety innovations and global market expansion.

Citigroup Global Markets Australia has announced a fully franked AUD 1.11 dividend for WES CitiFirst Self-Funding Instalments, aligning key dates with WES ordinary shares and reducing outstanding loan amounts on warrants.

Fat Prophets Global Contrarian Fund Ltd has reported a robust 56% increase in net profit for the year ended 30 June 2025, driven by strong investment returns and a leveraged global equity portfolio. The company also declared a fully franked special dividend, reflecting confidence in its ongoing performance.

HALO Technologies reports a significantly improved half-year net loss and secures verbal FCA approval for its UK platform, while preparing to launch Managed Funds in Australia.

Argent BioPharma reported a net loss of A$17.84 million for FY2025, reflecting a strategic pivot towards core drug development and clinical advancement. The company secured key EU approvals and raised significant capital to support its neuro-immune modulatory pipeline.

Uscom Limited reported a 25% decline in revenue to $3.16 million and a 59% increase in net loss to $3.3 million for FY25, reflecting significant global headwinds. Despite setbacks, the company advanced new product approvals and secured funding to navigate ongoing challenges.

Streamplay Studio’s FY25 preliminary results reveal a striking 121% income surge, driven by the strategic acquisition of North American game studio Noodlecake, positioning the company for a $10 million annual income trajectory.

Orthocell Ltd reported a record $9.23 million revenue for FY25, driven by strong sales of its nerve repair and dental products, alongside securing US FDA clearance for its flagship nerve repair device Remplir. The company is poised for accelerated growth as it expands its global commercial footprint.

Tissue Repair Ltd reported a 27.3% revenue increase to $3.22 million for FY25, driven by new distribution deals and regulatory progress, while continuing to invest heavily in clinical trials and manufacturing scale-up, resulting in a $4.24 million loss.

Staude Capital Global Value Fund Limited (GVF) reported a robust FY2025 with a 15.8% rise in adjusted pre-tax NTA and a fully franked dividend of 3.3 cents per share, underpinned by its discount capture strategy.

Staude Capital Global Value Fund Limited reported a 21% increase in net profit after tax for FY2025, driven by strong portfolio returns and a successful discount capture strategy. The company also declared a fully franked final dividend of 3.3 cents per share and completed a $16.9 million wholesale placement.